Learning Objectives:

1. Understand why traditional approaches for dose selection are not suitable for targeted therapies

2. Describe how randomized dose trials can support dose optimization for cancer drugs

3. Identify why performing dose optimization early in cancer drug development is beneficial

Session date: 
03/07/2022 - 12:00pm to 1:00pm CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Mirat Shah, MD, MHS